Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

导出原文传递

翻译打印收藏纠错

作者： Xin,Miao ^[1] ; Liviawati S.,Wu ^[2] ; Shun Xin Wang,Lin ^[3] ; Yan,Xu ^[4] ; Yang,Chen ^[5] ; Yuki,Iwaki ; Rachel,Kobos ; Tara,Stephenson ; Kristy,Kemmerer ; Clarissa M.,Uhlar ; Arnob,Banerjee ; Jenna D.,Goldberg ; Danielle,Trancucci ; Amit,Apte ; Raluca,Verona ; Lixia,Pei ; Rachit,Desai ; Kathleen,Hickey ; Yaming,Su ; Daniele,Ouellet ; Mahesh N.,Samtani ; Yue,Guo ; Alfred L.,Garfall ; Amrita,Krishnan ; Saad Z.,Usmani ; Honghui,Zhou ; Suzette,Girgis

作者单位： Janssen Research & Development ^[1] Janssen Pharmaceutical KK ^[2] Abramson Cancer Center, Perelman School of Medicine,University of Pennsylvania ^[3] City of Hope Comprehensive Cancer Center ^[4] Memorial Sloan Kettering Cancer Center ^[5]

发布时间 2023-10-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Targeted oncology

2023年18卷5期

667-684页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Targeted oncology

相似文献

Targeted oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Targeted oncology

相似文献

Targeted oncology

相关期刊

检索历史清除